- Research Article
- 10.1016/j.mito.2026.102138
Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy.
- Jul 01, 2026
- Mitochondrion
- Hacer Durmus + 6 more +6
Publications from 2021 to 2026
Showing 10 of 1,012 papers
Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy.
Efficacy of fascial manipulation in musculoskeletal pain management: A decade in review (2015-2025).
Quinoline-imidazo[1,2-a]pyridine conjugates as potential antioxidant agents: Synthesis, experimental and theoretical approaches
Comment on "The Contribution of Voice Therapy to Voice Quality and Quality of Life in Patients With Early Glottic Cancer Treated With Transoral CO2 Laser Microsurgery".
Beyond the knee: postural effects of gait retraining.
Multifactorial protective effects of boric acid against postoperative intra-abdominal adhesions in a rat model.
Traumaticbirth perception of women who experienced homebirth versus hospital birth: A case-control study from Türkiye.
Assessing public health training in Southeast Asia and the United Kingdom: A comparison of competency development for delivering the Essential Public Health Functions.
Comparison of sensory processing skills in 7-12 month old colic and non-colic infants.
Prognostic significance of incorporating SpO2 recovery time to the 6-minute walk test protocol and to a modified GAP index risk prediction model in patients with idiopathic pulmonary fibrosis.
The prognostic potential of SpO2 recovery time recorded during 6-min walk test (6MWT) remains unexplored in the setting of idiopathic pulmonary fibrosis (IPF). This study aimed to investigate prognostic significance of cardiopulmonary recovery time after the 6MWT and the utility of a modified gender-age-physiology (GAP) index incorporating SpO2 recovery time instead of DLCO as a predictive model in IPF patients. A total of 64 patients with IPF (mean±SD age: 61±10.2 years, 79.7% were males) were included in this retrospective cohort study. Cardiopulmonary recovery time (SpO2 recovery time and heart rate recovery [HRR] time in seconds), GAP index (gender, age, forced vital capacity [FVC] and diffusion capacity [DLCO]) and modified GAP index (gender, age, FVC, SpO2 recovery time) scores were recorded. SpO2 recovery time and modified GAP index predicted the increased risk of overall adverse events (OR 1.017, p=0.002 and OR 1.667, p<0.010, respectively). SpO2 recovery time at a cut-off value of >160 s (AUC: 0.813, p<0.001) and modified GAP index at a cut-off value of >3.5 (AUC: 0.762, p<0.001) were able to discriminate patients at risk of adverse clinical outcomes. Overall survival (OS) time was significantly longer in patients with SPO2 recovery time <160 s than in those with SPO2 recovery time ≥160 s (mean 24.3 vs. 8.5 months, Log-rank p value <0.001). Incorporating SpO2 recovery time to the 6MWT protocol and to a modified GAP index may improve mortality risk prognostication in IPF, supporting the utilization of continuous SpO₂ monitoring and recovery analysis during routine 6MWT.
Read more